Timing infliximab therapy in pediatric Crohn's disease.
Kirschner
Barbara S
BS
Huo
Dezheng
D
D000293:Adolescent; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D003424:Crohn Disease / Q000188:drug therapy*; D003627:Data Interpretation, Statistical; D004334:Drug Administration Schedule; D005765:Gastrointestinal Agents / Q000008:administration & dosage* / Q000009:adverse effects; D006801:Humans; D007155:Immunologic Factors / Q000008:administration & dosage* / Q000009:adverse effects; D000069285:Infliximab; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D012074:Remission Induction; D012107:Research Design; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D007155:Immunologic Factors; D000069285:Infliximab